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ABSTRACT In membranes purified from human blood plate-
lets, basal guanosine triphosphate (GTP) hydrolysis is reduced by
a factor of -6 by exposure to N-ethylmaleimide (10 mM). This
decreased background enables the detection of an additional GTP
hydrolysis in the presence of prostaglandin E1 (PGE1). The PGE1-
stimulated GTPase has several properties correlated with PGE1-
stimulated adenylate cyclase in this preparation. The two enzymes
have similar dose-response relationships (half-maximal stimula-
tion at 0.1 tM PGE1). Exposure to cholera toxin blocks the PGE1-
stimulated GTPase and activates adenylate cyclase. Both enzymes
are activated by submicromolar concentrations of GTP, although
the K. for the GTPase is about 10 times greater than that for the
adenylate cyclase. The data are discussed in relation to the hy-
pothesis that hormone-stimulated adenylate cyclase (i) is activated
as a regulatory component binds a molecule ofGTP and (ii) is deac-
tivated as this molecule is hydrolyzed.
Guanyl nucleotides play a central role in the hormonal stimu-
lation of adenylate cyclase in various tissues. For cases where
the point has been carefully studied, such stimulation is abso-
lutely dependent on the presence ofGTP or certain ofits analogs
(1). The hypothesis has arisen that a regulatory subunit of the
cyclase (i) binds GTP as the cyclase is activated and (ii) hydro-
lyzes the GTP as the cyclase is again deactivated. This concept
has received strongest support for the turkey erythrocyte mem-
brane. Because this preparation has a low basal level of GTP
hydrolysis, it was possible to observe an increment of GTPase
activity produced by adrenergic hormones (2, 3). This hormone-
stimulated GTPase has several properties expected of a system
that regulates the adenylate cyclase activity of these membranes.
For other membrane preparations, there is less direct evi-
dence that GTP is hydrolyzed by a component of adenylate cy-
clase. A persistent activation is produced by GTP analogs whose
f3,y-phosphate bond cannot be hydrolyzed enzymatically and
by cholera toxin, which blocks the GTPase in turkey erythro-
cytes (4). More direct proof would involve a demonstration of
GTP hydrolysis that shares the properties of hormone-stimu-
lated adenylate cyclase: (i) the dose-response relationship
should resemble that for cyclase stimulation; (ii) the GTPase
should be active at low GTP concentration, with a Km of <1
X 10-6 M; and (iii) the GTPase should be blocked by cholera
toxin. We have verified these concepts for the prostaglandin-
stimulated adenylate cyclase of membranes purified from hu-
man platelets. The measurements are made possible by the fact
that exposure to N-ethylmaleimide (MalNEt) markedly de-
creases basal GTP hydrolysis but apparently not hormone-stim-
ulated GTPase associated with cyclase (2).
Adenylate cyclase in human platelet membranes displays the
additional property of inhibition by a2-adrenergic agonists (5).
This inhibition requires guanyl nucleotides, albeit at a higher
concentration than required for adenylate cyclase activation (6,
7). The experiments thus afforded the opportunity to test
whether this inhibition is accompanied by a change in GTPase
activity.
MATERIALS AND METHODS
ATP (GTP-free) and guanyl-5'-yl imidodiphosphate (p[NH]ppG)
were from Boehringer Mannheim; prostaglandin E1 (PGE1) was
a gift from Upjohn; adenyl-5'-yl imidodiphosphate (p[NH]ppA)
was from ICN or Sigma; 2-mercaptoethanol was from Eastman;
radiochemicals were from The Radiochemical Centre, Amer-
sham. Cholera toxin was obtained directly from Makor Chem-
icals, Jerusalem, or through its distributor, Sigma. Other chem-
icals were from Sigma.
Platelet Membrane Preparation. Whole blood was obtained
from donors who had taken no aspirin-containing drugs for 2 wk
prior to blood donation, and platelet membranes were prepared
by the glycerol-lysis technique (8) as described by Steer and
Wood (7). At all stages of the experiments, pelleted membranes
were resuspended gradually by using a Teflon rod (7). Aden-
ylate cyclase and GTPase assays were performed within 6 hr of
blood donation. Protein was determined by the method of
Lowry et al (9) with bovine serum albumin as a standard.
Turkey Erythrocyte Membranes. These were prepared as
described by Steer and Levitzki (10).
Cholera Toxin Treatment. This was performed essentially
as described by Kaslow et aL (11). Cholera toxin (200 ,ug/ml)
was activated by incubation for 10 min at 30°C in 2 mM di-
thiothreitol/50 mM sodium phosphate buffer, pH 7.1/100 mM
NaCV5 mM MgCl2, with 0.2 mg of ovalbumin per ml. This
solution was added in equal volume to membranes suspended
(1.5 mg/ml) in 1 mM ATP/1 mM nicotinamide adenine dinu-
cleotide/200 ,uM GTP/50 mM sodium phosphate buffer, pH
7.1, with 100 units of creatine kinase per ml. The toxin and
membranes were incubated for 10 min at 30°C, and the reaction
was stopped by spinning at 20,000 x g for 10 min. Membranes
were then washed twice in 10 mM Tris-HCl, pH 8/0.1 mM
EDTA/0.25 M sucrose, followed by one wash in Tris/EDTA
without sucrose. Pellets were resuspended in 10 mM Tris. This
suspension was divided into portions destined for the adenylate
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cyclase assay (see below) or for MalNEt treatment followed by
the GTPase assay.
Adenylate Cyclase Assay. The reaction mixture had a final
volume of 0.2 ml containing 0.1-0.3 mg of platelet membrane
protein per ml. The enzyme was assayed under "standard" and
"GTPase" conditions. In the former case, the concentrations of
agents in the assay were: Tris HCl (pH 8.0), 30 mM; MgCl2, 10
mM; caffeine, 33 mM; creatine phosphate, 5 mM; creatine ki-
nase, 50 units/ml; and [a-32P]ATP (50-100 cpm/pmol), 0.2
mM. Incubations were for 10 min at 30TC. Under "GTPase"
assay conditions, the incubation was for 5 min at 370C, and final
concentrations of reagents in the assay mixture were exactly as
described for the GTPase assay (see below), except that the ra-
diochemical was [a-32P]ATP.
In either case, the reaction was terminated by addition of a
solution containing 4 mM ATP, 1.4 mM cAMP, and 2% sodium
dodecyl sulfate. [3H]cAMP (5-10,000 cpm per assay tube) was
added, and [32P]cAMP was collected by the method of Salomon
et aL (12). Recovery of [32P]cAMP was corrected by using the
value obtained for [3H]cAMP recovery (50-80%).
MalNEt Treatment. This was performed essentially as de-
scribed by Cassel and Selinger (2). Membranes (0.5-1 mg of
protein per ml) were incubated in 10 mM MalNEt for 30 min
at 0°C. The incubation was terminated by addition of 15 mM
2-mercaptoethanol. After an additional 5 min at 0°C, the re-
action was diluted 1:10 (vol/vol) with 50 mM imidazole HCl,
and membranes were pelleted at 20,000 X g for 10 min. Mem-
branes were resuspended in imidazole buffer and used for the
GTPase assay.
GTPase Assay. This was performed by liberation of 32Pi from
[y-32P]GTP as described by Cassel and Selinger (13). The re-
action mixture (final volume, 100 ,l.) contained 0.25 ,uM
[[a-32P]GTP (2.5-10 X 103 cpm/pmol), 0.1 mM ATP, 6 mM
MgCl2, 0.5 mM p[NH]ppA, 2 mM 2-mercaptoethanol, 3 mM
creatine phosphate, 0.1 mM EGTA, 3 units of creatine kinase,
and 50 mM imidazole HCl buffer (pH 6.7). The reaction tubes,
minus the membranes, were preincubated at 37°C for 15 sec.
The reaction was initiated by adding 10-40 ,g of the mem-
branes and was terminated after 10 min by adding 0.5 ml of a
suspension of5% charcoal (acid washed, Norit A) in ice-cold 20
mM phosphate buffer (pH 7.1). After at least 5 min at 30°C, the
suspension was centrifuged (1000 X g for 5 min) and 200 ,l of
the supernatant was assayed using Cerenkov radiation. With
this method, 1-5% of the added 32Pi was recovered in assays
without added membranes, presumably because the [y-32P]GTP
hydrolyzed spontaneously during-storage; this value was sub-
tracted from the data with membranes. Assays were performed
in triplicate or quadruplicate.
RESULTS
Critique of the MalNEt Method. With the GTPase assay
system developed by Cassel and Selinger (2, 13), human platelet
membranes had a basal activity of about 60 pmol/min per mg
of protein (Table 1). PGE, produced a barely significant in-
crease of about 5 pmoVmin per mg. The basal activity was re-
duced by a factor of -6 by exposure to MalNEt at 10 mM, ren-
dering the PGE, stimulation more evident. In eight preparations
studied after MalNEt exposure, the PGE1 stimulation amounted
to an increase of 46 ± 7% (mean ± SEM) over basal activity.
A higher MalNEt concentration reduced both the basal and
PGE,-stimulated activity, producing no further improvement
in the resolution of the assay (Table 1).
The MalNEt treatment has the disadvantage of blocking
adenylate cyclase activity. Exposure to MalNEt might also mod-
ify the prostaglandin-stimulated GTPase activity, vitiating stud-
ies with this technique. To evaluate this possibility, we ex-
Table 1. Effects of MalNEt treatment on GTPase in human
platelet membranes
GTPase activity,*
With PGE,
MalNEt, No With With and
mM additions epinephrine PGE1 epinephrine
0 59.3 ± 1.0 62.9 ± 1.8 64.5 ± 1.6 65.7 ± 1.9
10 9.7 ± 0.4 10.2 ± 0.2 14.8 ± 0.4 14.8 ± 0.6
50 6.7 ± 0.2 6.7 ± 0.3 9.8 ± 0.5 9.6 ± 0.4
Membranes were exposed to MalNEt for 30 min at 0°C. Epinephrine
was 100 ,uM with 1 ,uM propranolol.
* In pmol/min per mg of protein, expressed as mean ± SEM of four
replicates.
ploited the turkey erythrocyte system, whose low basal GTPase
activity allows measurements of epinephrine stimulation both
before and after MalNEt treatment. The data (Fig. 1) show that
MalNEt treatment produced little or no change in the Km for
GTP and a small (44%) decrement in the maximal GTPase ac-
tivity. Thus, hormone-stimulated GTPase is not greatly affected
by the MalNEt treatment.
Dose-Response Characteristics for the GTPase and Cy-
clase. Earlier studies have shown that prostaglandin-stimulated
adenylate cyclase is stimulated to half-maximal activity at PGE,
concentrations on the order of 0.1 ,uM (7). The present exper-
iments confirmed these data and showed that the PGE,-stim-
ulated GTPase displays strikingly similar dose-response char-
acteristics (Fig. 2).
.Effects of Cholera Toxin. Cholera toxin affects human plate-
let membranes analogously to its action on turkey erythrocytes:
it activates adenylate cyclase (14), presumably by blocking hor-
mone-stimulated GTPase (Table 2). Because human platelet
membranes have significant basal adenylate cyclase, it was of
interest to determine whether basal GTPase activity was also
affected by exposure to cholera toxin. There was a small de-
crease in the experiment of Table 2, but this was not observed
6
0~~~~~~
. 4
0~~~~~~~~~~
0
0 0.2 0.4 0.6 0.8 1.0
GTP, IAM
FIG. 1. Effects of MalNEt treatment on epinephrine-stimulated
GTPase in turkey erythrocyte membranes. Data show the increase in
GTP hydrolysis in the presence of 0.1 mM 1-epinephrine. Lines are
theoretical hyperbolic functions. o, Normal (V, 7.7 pmol/min per
mg of protein; Km, 2.5 x 10-7 M). *, MalNEt-treated (Vm,,,, 4.4 pmol/
min per mg of protein; Km, 1.7 X 10-7 M).
Proc. Natl. Acad. Sci. USA 79 (1982)
Proc. NatL Acad. Sci. USA 79 (1982) 721
4
U01.4*,A" S
as 2
0) "
'0
. 0
-4
*S 1D
04
3
2
1
0
0 109 1o-8 10-7 10-6 10-5
PGE1, M
FIG. 2. Dose-response characteristics for the PGE,-stimulated
adenylate cyclase (Upper) and GTPase (Lower). Lines are theoretical
hyperbolic functions. (Upper) Via, 3.5 nmol/min per mg of protein;
Km. 1 x 10-7 M. (Lower) Van,,, 6.2 pmol/min per mg of protein; K.,
1 x 10-7 M. Standard errors of the mean are shown where they exceed
the size of the symbols.
in a second experiment under similar conditions. In both ex-
periments, hormone-induced GTPase was reduced by a factor
of =3 after exposure to cholera toxin. Therefore, the cholera
toxin specifically decreases hormone-stimulated GTPase, as
observed for turkey erythrocytes (4).
GTP Concentration Dependence. Human platelet mem-
branes showed both basal and PGE1-stimulated GTPase for
GTP concentrations in the range of 0.05-10 ILM (Fig. 2). In an
experiment to explore the range between zero and 2 JIM, we
found that the basal GTPase was characterized by a component
with aKm of 1 x 10-7M and a second component, presumably
with a much higher Km, whose rate increased linearly with GTP
concentration (data not shown).
However, the prostaglandin-stimulated GTPase was char-
acterized by a Km several times larger than 1 x 10-7 M. In the
experiments of Fig. 3 and Fig. 4b, the Km was 6 X 10-7 M; and
two similar experiments gave values of 4 and 6 x 10-7 M. By
contrast, the prostaglandin-stimulated adenylate cyclase is ac-
tivated by much lower GTP concentrations (6, 7).
Table 2. Effects of cholera toxin on GTPase and
adenylate cyclase
Enzyme activity*
Addition No pretreatment Cholera toxin
GTPase
None 11.5 ± 0.9 7.5 ± 0.7
PGE1 19.9 ± 1.1 10.3 ± 0.7
Adenylate cyclase
None 50 ± 2.5 180 ± 9
GTP 100 ± 5 690 ± 35
p[NH]ppG 507 ± 25 491 ± 25
* In pmol/min per mg of protein, expressed as mean ± SD.
FIG. 3. GTP concentration dependence of the adenylate cyclase
(Upper) and GTPase (Lower). A, PGE1; A, basal; 9, PGE1-stimulated
GTPase. These data are analyzed further in Fig. 4B.
To provide an accurate comparison between the two en-
zymes, we assayed adenylate cyclase under the same conditions
used in the GTPase assay, although the MalNEt treatment was
omitted. (The adenylate cyclase activity was only about 1/6th
of the normal value under these suboptimal conditions.) Half-
maximal stimulation was observed at 0.04 AM GTP. There was
some activity even with no added GTP, perhaps because the
membrane preparation itself contributed guanyl nucleotides.
If so, the Km for adenylate cyclase was about 6 X 10-8 M, or
about 1/10th the Km for GTP hydrolysis.
If the membrane preparation contributed GTP, this would
also artifactually increase the measured Km for the GTPase by
the amount contributed. Two observations render it unlikely
that such a mechanism significantly distorted the GTPase re-
sults. First, a Km of 10-7 M was measured for basal GTPase,
suggesting that endogenous GTP is below this level. Second,
control experiments showed that the rate of 32Pi release was
linear with the amount of membrane protein added.
Effects of Epinephrine. We studied the effects of epineph-
rine on GTPase and on adenylate cyclase at two GTP concen-
trations, 0.25 AuM (the usual value in our experiments) and 5
AM (where the largest epinephrine inhibition of adenylate cy-
clase is observed). At both concentrations, epinephrine pro-
duced clearcut inhibition of adenylate cyclase, and PGE1 pro-
duced clearcut stimulation of GTPase; yet epinephrine had no
effect on GTPase in either the presence or absence of PGE,(Table 3). The contrast is particularly clear at 5 AM GTP in the
absence of PGE1: epinephrine decreased adenylate cyclase ac-
tivity to 56% of the control value, with no measurable change
in GTPase activity.
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FIG. 4. Further comparison of GTP concentration effects on PGEI-stimulated adenylate cyclase (A) and GTPase (B). The adenylate cyclase
activity was measured under the same conditions as those used in the GTPase assay. For B, a straight line was fit to the PGEI-stimulated GTPase
at GTP concentrations -3 pM in the experiment of Fig. 3. This line presumably represents a low-affinity PGE,-stimulated GTPase and was sub-
tracted from the data. This correction is equivalent to subtracting the radioactivity released at high concentrations of unlabeled GTP in the presence
of PGE1 (2). Resulting values are plotted. Solid lines are theoretical hyperbolic functions. (A) Va,,, 110 pmol/min per mg of protein; Km, 4 X 10-8
M. (B) Vr,,, 8.2 pmol/min per mg of protein; Km, 6 x 10-7 M.
DISCUSSION
GTPase and Cyclase. The data leave little doubt that the
prostaglandin-stimulated GTPase activity is closely correlated
with activation of adenylate cyclase. The dose-response char-
acteristics match for the two enzymes, they are affected as ex-
pected by cholera toxin, and both are activated by GTP at sub-
micromolar concentrations. This correlation seems more direct
than for the prostaglandin-stimulated GTP hydrolysis recently
reported for human mononuclear cells (15). Good correlations
between GTPase and adenylate cyclase also have been reported
for activation by pancreozymin (16) and glucagon (17) in addition
to the original observations with ,(3adrenergic agonists in eryth-
rocytes (2, 18).
There is, however, an interesting discrepancy between the
detailed GTP concentration dependence of the two enzymes.
Adenylate cyclase activity is half-maximal at about 4 X 10-8 M
GTP; the Km for the GTPase is 10-fold higher. The Km values
for the two enzymes would be equal in the simple scheme where
(i) a molecule of cyclase is activated as a molecule ofGTP binds
to a regulatory component and (ii) cyclase is deactivated as GDP
and Pi are released. Evidently events at the GTP binding site
are coupled in a less direct fashion to the cyclase.
Table 3. Comparison of epinephrine effects on GTPase and
adenylate cyclase
GTP, % change by epinephrine
AuM GTPase Adenylate cyclase
Without PGE1
0.25 +2± 4 -12± 3
5.00 +7± 8 -44±10
With PGE1, 1.0 ,AM
0.25 -9± 8 -10± 6*
5.00 -5 ± 13 -26 ± 5
Epinephrine concentration was 10 or 100 pM, with 1 juM propran-
olol. Values are expressed as the mean ± SEM of four to six
experiments.
* Single experiment.
Inhibition by Epinephrine. Our experiments disclose no ef-
fect of epinephrine on GTPase under conditions where epi-
nephrine produces clear inhibition of adenylate cyclase. These
data must be viewed as incomplete because (i) the GTPase
measurements have a poor signal-to-noise ratio in the absence
of MalNEt treatment (Table 1); (ii) MalNEt treatment, which
reveals the PGE,-stimulated GTPase, might conceivably have
modified some component of the inhibitory system. Nonethe-
less, the data are consistent with the observation that epineph-
rine does not alter the dynamics of cyclase activation and in-
activation by GTP analogs; these dynamics are thought to
provide a measure of the rate constants for the GTPase cycle
(unpublished observations).
Note Added in Proof. Aktories and Jacobs (19) have reported that ep-
inephrine stimulates a GTPase in human platelet membranes.
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